PATENT CLAIM ANALYSIS

Application Number: 15746398
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["435", "325000"]

Abstract:
Factors for extending the ability of isolated pluripotent stem cells to generate extraembryonic lineages in vivo, following in vitro culture, herein, chemical extenders of pluripotency (CEP). Methods of extending the ability of a pluripotent cell to generate embryonic and extraembryonic lineages. The cell to be reprogrammed is contacted with effective amounts of the CEPs for a sufficient period of time to reprogram the cell into a chemically induced extended pluripotent cell (ciEPSC). ciEPSC are identified as an extended pluripotent cell based on properties including: (i) morphologically and (ii) functionally for example, based on their ability contribute to both TE and ICM, in vivo. The ciEPSCs can be cultured or induced to differentiate into cells of a desired type, and used in a number of applications, including but not limited to cell therapy and tissue engineering.

Claim (Index 20):
A ciEPSC obtained by the method of  claim 7 ,\n and preferably wherein expression of at least one marker selected from the group consisting of TBX3 and GBX2 is upregulated when compared to untreated corresponding cells isolated from the same organism as the donor cell or wherein one gene selected from the group consisting of HOXA1 (Homeobox A1), MIXL1 (Mix1 homeobox-like 1), DERA (deoxyribose-phosphate aldolase), CHD7(Chromodomain Helicase DNA Binding Protein 7)), CHD4(Chromodomain Helicase DNA Binding Protein 4), MIXL1 and LEF1 (Lymphoid enhancer-binding factor 1), is upregulated when compared to an untreated cell; expression of at least one marker selected from the group consisting of OCT4, NANOG, KLF2, SOX2, and UTF1(undifferentiated embryonic cell transcription factor) is down regulated when compared to untreated corresponding cells isolated from the corresponding organism as the donor cell; LIF signaling is enhanced, when compared to untreated corresponding cells isolated from the corresponding organism as the donor cells; the cell can contribute to both embryonic and extraembryonic lineages following in vivo transplantation into mouse embryos; and/or the basal level of at least one extraembryonic marker selected from the group consisting of CDX2, GATA6, HAND1 and EOMES is upregulated at the mRNA level.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 86.0
- Lexical Diversity: 1.81395
- Patent Class: 435.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14904195', '09436164', '12108852', '14735841', '12164795']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6246118674091
- 35 USC 102 Novelty (BERT): 0.5218443185865039
- Combined Prediction Score: 0.6143351125268405
- Mean Citation Score: 321.480656
- Max Citation Score: 338.71844
- Similarity Product: 229.5868714545512

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test